VEGFR3 Agonist Meningeal Lymphatic Vessel Diameter
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases such as Alzheimer's disease lack effective methods to modulate lymphatic vessels in the central nervous system, leading to inadequate fluid flow and accumulation of amyloid-beta plaques, which contribute to cognitive impairment.
Innovation Solution
Administration of a VEGFR3 agonist with at least 85% sequence identity to VEGF-c or VEGF-d to the meningeal space to increase the diameter of meningeal lymphatic vessels, enhancing fluid flow and clearance of amyloid-beta plaques in the central nervous system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If current treatments for neurodegenerative diseases are used, then cognitive impairment and amyloid-beta plaque accumulation occur, but lymphatic vessel modulation and fluid flow enhancement are insufficient
Solution Approach 1:
The patent changes the physiological parameters of lymphatic vessels by administering VEGF-C or VEGF-D proteins that bind to VEGFR-3 receptors, inducing lymphangiogenesis and increasing vessel diameter. This parameter change in vessel structure directly enhances fluid flow clearance efficiency, addressing the insufficient lymphatic modulation in current neurodegenerative disease treatments.
2Productivity
If lymphatic vessel diameter is increased through VEGF-C or VEGF-D administration, then fluid flow and amyloid-beta clearance are enhanced, but the complexity of treatment protocol increases
Solution Approach 1:
The patent uses VEGF-C or VEGF-D proteins as intermediary substances that mediate between the administered treatment and the lymphatic vessel system. These proteins serve as biological messengers that naturally bind to VEGFR-3 receptors on lymphatic endothelial cells, triggering downstream signaling pathways that promote lymphangiogenesis without requiring direct genetic manipulation or complex surgical interventions.
3Length of stationary object
If VEGF-C or VEGF-D is administered to modulate lymphatic vessels, then meningeal lymphatic vessel diameter increases, but the risk of off-target effects and immune response increases
Solution Approach 1:
The patent achieves localized modulation of meningeal lymphatic vessels through targeted administration of VEGF-C or VEGF-D to the central nervous system. The proteins exhibit selective binding to VEGFR-3 receptors that are predominantly expressed on lymphatic endothelial cells, particularly in the meningeal lymphatic vessels. This local quality specificity ensures that the therapeutic effect is concentrated where needed while minimizing systemic off-target effects and immune responses.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly increases fluid flow and reduces the quantity of amyloid-beta plaques, thereby improving cognitive function and alleviating symptoms of neurodegenerative diseases by enhancing the drainage and clearance of molecules from the brain.
Implementation Method 1
Administration of a VEGFR3 agonist with at least 85% sequence identity to VEGF-c or VEGF-d to the meningeal space to increase the diameter of meningeal lymphatic vessels
Implementation Method 2
VEGFR3 agonist...increase the diameter of meningeal lymphatic vessels
Implementation Method 3
increasing fluid flow in the central nervous system...by enhancing the drainage and clearance of molecules from the brain
Data Source
Figure 1A~1C
Figure 1D~1E
Figure 1F~1G
AI summary
In some embodiments herein, methods, compositions, and uses for modulating lymphatic vessels of the central nervous system are described. In some embodiments, methods, compositions, or uses for treating, preventing, or ameliorating symptoms of a neurodegenerative disease comprise by increasing flow via meningeal lymphatic vessels are described. In some embodiments, methods, compositions, or uses for treating, preventing, or ameliorating symptoms of inflammatory neurological disease be inhibiting or preventing immune cell migration through meningeal lymphatic vessels are described